Sivia Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.26M Buy
3,555
+1,734
+95% +$1.77M 0.52% 25
2026
Q1
$1.67M Sell
1,821
-634
-26% -$643K 0.32% 65
2025
Q4
$2.64M Buy
2,455
+177
+8% +$169K 0.53% 22
2025
Q3
$1.74M Buy
2,278
+307
+16% +$228K 0.49% 26
2025
Q2
$1.54M Sell
1,971
-121
-6% -$94K 0.52% 22
2025
Q1
$1.73M Buy
2,092
+248
+13% +$206K 0.81% 20
2024
Q4
$1.42M Buy
1,844
+32
+2% +$26.5K 0.71% 21
2024
Q3
$1.61M Buy
1,812
+5
+0.3% +$4.5K 0.95% 20
2024
Q2
$1.64M Sell
1,807
-61
-3% -$48.8K 1.09% 18
2024
Q1
$1.45M Buy
1,868
+89
+5% +$63.3K 0.99% 18
2023
Q4
$1.04M Buy
+1,779
New +$1.04M 0.79% 20

Other funds holding LLY

Sivia Capital Partners's LLY Position: Q2 2026 in Review

Sivia Capital Partners increased its Eli Lilly (LLY) stake by 95% in Q2 2026, buying an estimated $1.77M and bringing the position to 3,555 shares worth $4.26M. The position accounts for 0.52% of the portfolio, ranked #25.

Sivia Capital Partners first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,393 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Sivia Capital Partners held 3,555 shares of Eli Lilly worth $4.26M as of Q2 2026.
  • Sivia Capital Partners bought 1,734 Eli Lilly shares in Q2 2026, an estimated $1.77M.
  • Eli Lilly made up 0.52% of Sivia Capital Partners's portfolio in Q2 2026, its #25 holding.
  • Sivia Capital Partners first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.